All long-acting GLP-1 receptor agonists are cardiovascularly safe, and several (liraglutide, semaglutide, dulaglutide) actually reduce heart attacks and strokes in type 2 diabetes patients.
CV risk reductionLiraglutide, semaglutide, and dulaglutide significantly reduced major adverse cardiovascular events in outcome trials
What the researchers found
Long-acting GLP-1 RAs are cardiovascularly safe, with liraglutide, semaglutide, and dulaglutide demonstrating significant cardiovascular risk reduction in outcome trials.
Why it matters
Cardiovascular disease is the leading cause of death in T2D patients. GLP-1 RAs that reduce cardiovascular events while lowering blood sugar address both conditions simultaneously.
The numbers in context
6 GLP-1 RAs; all noninferior for MACE; 3 significantly reduced MACE; FDA label updates for 3 drugs
How the study worked
Review of completed cardiovascular outcome trials for all long-acting GLP-1 RAs, analyzing major adverse cardiovascular event (MACE) endpoints.
Who was studied
Type 2 diabetes patients in large cardiovascular outcome trials
What this study cannot tell us
CVOT designs vary between agents, making direct comparisons difficult. Most trials studied high-CV-risk populations.
How to read the evidence
Review of large-scale randomized cardiovascular outcome trials — the highest level of clinical evidence.
When this study was published
Published in 2020. Additional CVOT data and real-world evidence have since further supported these findings.
The bigger picture
These cardiovascular benefits have transformed diabetes treatment guidelines, making GLP-1 RAs a first-line recommendation for T2D patients with established cardiovascular disease.
Questions still open
- Do GLP-1 RAs provide cardiovascular benefits in T2D patients without established CVD?
- Which GLP-1 RA provides the greatest cardiovascular protection?
- Are cardiovascular benefits a class effect or agent-specific?
Common questions
Do GLP-1 drugs protect the heart?
Should all diabetics take GLP-1 drugs?
Read the original research
Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
JAAPA : official journal of the American Academy of Physician Assistants, 33(S8 Suppl 1), 19-30
Citation
Urquhart, Scott; Willis, Stephen. (2020). Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.. JAAPA : official journal of the American Academy of Physician Assistants, 33(S8 Suppl 1), 19-30. https://doi.org/10.1097/01.JAA.0000669452.63883.45